loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Pegfilgrastim reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Pegfilgrastim

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 11,435,344Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1 Neulasta/Peglasta

    02 7G-Lasta

    03 9Neulasta

    04 6Neulasta/Peglasta

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Neulasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Neulasta

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Amgen

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 2,293

    2019 Revenue in Millions : 3,221

    Growth (%) : -29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Neulasta/Peglasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Neulasta/Peglasta

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 39

    2019 Revenue in Millions : 36

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 253

    2019 Revenue in Millions : 233

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Neulasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Neulasta

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Amgen

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 1,734

    2020 Revenue in Millions : 2,293

    Growth (%) : -24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Neulasta/Peglasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Neulasta/Peglasta

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 45

    2020 Revenue in Millions : 39

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 248

    2020 Revenue in Millions : 253

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Neulasta/Peglasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Neulasta/Peglasta

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 42

    2021 Revenue in Millions : 45

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 235

    2021 Revenue in Millions : 248

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Neulasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Neulasta

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Amgen

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 1,126

    2021 Revenue in Millions : 1,734

    Growth (%) : -35

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 215

    2022 Revenue in Millions : 235

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF